inotuzumab
ucb pharmaceuticals
['leusm', 'leukemia', '2018', 'inotuzumab']
#ash22 #leusm stelljes: 43 evaluable after 1+ cycles of ino. median age 64, 12 age 70+. spectrum of cd22 positivity. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)